The paper consistently treats “sex” (biological) and “gender” (socio-cultural) as interchangeable concepts, using the terms synonymously throughout the analysis. This conflation fundamentally weakens their entire framework. When they attribute differences in tumor location, immune response, or statin efficacy to “sex-based” biology, they’re ignoring that many of these disparities could be driven by gender-related factors: differences in healthcare-seeking behavior, dietary patterns, occupational exposures, or even how symptoms are reported and interpreted by clinicians. By not disentangling these, they’re making a causal leap their data simply cannot support. The studies they cite mostly report associations, and without controlling for gender-related confounders, attributing everything to chromosomal or hormonal differences is a major overreach.
Given that you’ve conflated sex and gender throughout, how can you confidently attribute the observed disparities in tumor location and treatment response to biological sex rather than to gender-driven differences in screening uptake, diet, or healthcare access that weren’t controlled for in the source studies?
You advocate for sex-specific screening protocols based on tumor location prevalence. But since there’s significant overlap (41% of women still get left-sided tumors), wouldn implementing sex-specific guidelines based on group-level data risk missing a substantial number of cases in both sexes, potentially doing more harm than good?